Company profile
IDEAYA BIOSCIENCES, INC.
NASDAQ:IDYABiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DAROVASERTIB | phase3 | — | 6 | active |
| TUVUTROMSTAT | phase1 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05907954 | phase2 | active_not_recruiting | 2023-07-03 | 2027-04-30 | IDEAYA Biosciences | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma |
| NCT07503808 | phase1 | recruiting | 2026-02-24 | 2027-07-30 | IDEAYA Biosciences | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types |
| NCT07174583 | phase1_2 | recruiting | 2025-10-14 | 2029-07-01 | IDEAYA Biosciences | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer |
| NCT07277413 | phase1 | recruiting | 2026-03-04 | 2028-04-30 | IDEAYA Biosciences | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors |
| NCT05787587 | phase1 | active_not_recruiting | 2023-04-18 | 2026-10-01 | IDEAYA Biosciences | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors |
FDA applications (0)
No records yet.